Breakthrough Discovery: British Explorer Andrew ‘Sandy’ Irvine’s Partial Remains Believed to Be Found on Mount Everest After 100 Years
11.10.2024 08:00:00 CEST | Business Wire | Press release
Discovery Made by Expedition Team Led by Jimmy Chin During Mount Everest Climb for Upcoming National Geographic Documentary Film, Reported Exclusively on NatGeo.comEvidence Is First Possible Proof of Irvine’s Death Since Disappearing During 1924 Expedition With George Mallory, Whose Remains Were Found on Everest in 1999 by Conrad AnkerExclusive Photos NatGeo.com Story: https://www.nationalgeographic.com/adventure/article/sandy-irvine-body-found-everest
After 100 years of speculation surrounding his fate, the partial remains of Andrew Comyn “Sandy” Irvine are believed to have finally been discovered on Mount Everest. At age 22, Irvine vanished while attempting to conquer the world’s tallest peak on June 8, 1924, along with his climbing partner, renowned mountaineer George Mallory.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010214459/en/
A sock embroidered with "A.C. Irvine", along with a boot, has been discovered on the Central Rongbuk Glacier below the North Face of Mount Everest by a team led by Jimmy Chin. This is the first possible proof of Irvine's death since disappearing during a 1924 expedition. (credit: Jimmy Chin)
The discovery was made recently by a small team including National Geographic Explorer, photographer, Academy AwardⓇ-winning director and professional climber Jimmy Chin along with climbers and filmmakers Erich Roepke and Mark Fisher. What is believed to be Irvine’s foot, encased in a sock and boot, was found on the Central Rongbuk Glacier below the North Face of Everest at a lower altitude than Mallory’s remains were located. The partial remains – identified with his name stitched into the sock – are now in the possession of the China Tibet Mountaineering Association, which is responsible for climbing permits on Everest’s northern side.
The find was reported to the Royal Geographical Society - who jointly organized Mallory and Irvine’s expedition along with the Alpine Club - which at the time was only the third British climb on Mount Everest. It was also shared with Irvine’s great niece and biographer, Julie Summers – one of many living family relatives. The Irvine family has volunteered to compare DNA test results with the remains to confirm Irvine’s identity.
“Any expedition to Everest follows in the shadow of Irvine and Mallory,” said Chin. “We certainly did. And sometimes in life the greatest discoveries occur when you aren’t even looking. This was a monumental and emotional moment for us and our entire team on the ground, and we just hope this can finally bring peace of mind to his relatives and the climbing world at large.”
“It is remarkable that this discovery was made in the centenary year of Sandy’s disappearance,” said Summers. “I have lived with this story since I was a 7-year-old when my father told us about the mystery of Uncle Sandy on Everest. The story became more real when climbers found the body of George Mallory in 1999, and I wondered if Sandy’s body would be discovered next. A quarter of a century after that discovery, it seemed extremely unlikely that anything new would be found. When Jimmy told me that he saw the name A.C. Irvine on the label on the sock inside the boot, I found myself moved to tears. It was and will remain an extraordinary and poignant moment.”
Professor Joe Smith, director of the Royal Geographical Society, said of the discovery: “As joint organiser of the 1924 Everest expedition (with the Alpine Club), the Society deeply appreciates the respect Jimmy Chin’s team has shown Sandy Irvine’s remains and their sensitivity toward Sandy’s family members and others connected to that expedition. Sandy was an exceptional figure and made a significant contribution to our understanding of Everest and the Himalaya. This discovery of his remains provides an element of closure for his relatives and the wider mountaineering community, and we are grateful to Jimmy and his team for enabling this and ensuring Sandy is in safe hands. The Society will continue to assist Jimmy, his team and Sandy’s extended family during what will inevitably be a period of intense global interest.”
Irvine and Mallory were British mountaineers who disappeared in 1924 during an expedition organized by the Royal Geographical Society and Alpine Club to be the first to summit Everest. The mystery of whether they reached the summit before their death has intrigued climbers and historians for decades. Mallory’s body was discovered in 1999 by climber Conrad Anker, but until now, Irvine’s remains had never been found.
The team’s climb was funded by National Geographic Documentary Films for an upcoming documentary directed and produced by the Academy Award- and the BAFTA Award-winning team behind “Free Solo,” E. Chai Vasarhelyi and Chin, and their banner Little Monster Films.
Irvine Family Statement on the Discovery:
“The Irvine family is deeply moved to hear of the discovery of partial remains of Sandy Irvine. We are grateful to the mountaineering and film team, led by Jimmy Chin, who made the discovery and who have treated it with respect and professionalism. We are happy that the remains are now in the hands of the CTMA. Sandy Irvine was the youngest member of the 1924 Mount Everest expedition and was lost on the upper slopes of the mountain with George Mallory when the two disappeared on 8 June 1924.”
ABOUT JIMMY CHIN
Chin is a professional climber, skier, mountaineer, 20-year member of The North Face Athlete Team and National Geographic Explorer. Consistently over the past 20 years, Chin has led or participated in cutting-edge climbing and ski mountaineering expeditions to all seven continents and participated in the first and only American ski descent from the summit of Mount Everest. He is also a filmmaker and National Geographic photographer. He has worked with many of the greatest explorers, adventurers and athletes of our time, documenting their exploits in the most challenging conditions and locations in the world. Together with his wife, Elizabeth Chai Vasarhelyi, he has co-directed the films “Meru,” “Free Solo,” “The Rescue,” “Wild Life,” “Return To Space,” and their first scripted feature, “Nyad.” Their next documentary feature, “Endurance” premieres this weekend at the BFI London Film Festival. Chin and Vasarhleyi won the Best Documentary Oscar® in 2019 for “Free Solo.”
Exclusive Photos
NatGeo.com Story: https://www.nationalgeographic.com/adventure/article/sandy-irvine-body-found-everest
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010214459/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom